TransCode Therapeutics (NASDAQ:RNAZ) vs. Benitec Biopharma (NASDAQ:BNTC) Financial Analysis

Benitec Biopharma (NASDAQ:BNTCGet Rating) and TransCode Therapeutics (NASDAQ:RNAZGet Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Institutional & Insider Ownership

21.0% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 18.2% of TransCode Therapeutics shares are owned by institutional investors. 2.6% of Benitec Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Benitec Biopharma and TransCode Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Benitec Biopharma N/A -127.37% -108.35%
TransCode Therapeutics N/A -41.99% -33.95%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Benitec Biopharma and TransCode Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Benitec Biopharma 0 0 1 0 3.00
TransCode Therapeutics 0 0 0 0 N/A

Benitec Biopharma currently has a consensus target price of $10.00, suggesting a potential upside of 899.90%. Given Benitec Biopharma’s higher possible upside, equities research analysts plainly believe Benitec Biopharma is more favorable than TransCode Therapeutics.

Earnings and Valuation

This table compares Benitec Biopharma and TransCode Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Benitec Biopharma $60,000.00 136.21 -$13.88 million ($179.01) -0.01
TransCode Therapeutics N/A N/A -$6.84 million ($0.19) -10.53

TransCode Therapeutics has lower revenue, but higher earnings than Benitec Biopharma. TransCode Therapeutics is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Benitec Biopharma beats TransCode Therapeutics on 6 of the 10 factors compared between the two stocks.

Benitec Biopharma Company Profile (Get Rating)

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

TransCode Therapeutics Company Profile (Get Rating)

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA-based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Receive News & Ratings for Benitec Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.